

Nine months turnover at 25.5 M€

Radiology: important base effect during the 3rd quarter and delivery delays over the 4th quarter without impact on the 2022 exercise thanks to a sustained order book

Sustained progression of the **Bone densitometry** activity at the end of September and solid order book for the end of the year

Liège (Belgium) – **DMS Imaging** (previously ASIT Biotech) (**Euronext Brussels and Paris - BE0974289218 - DMSIM**), French specialist in the development, design, and manufacture of imaging systems, publishes its annual consolidated turnover for the nine first months of the 2022 exercise (period between January 1st to September 30th, 2022).

Non audited consolidated data in M€ IFRS standard	2019	2020	2021	2022	<i>Variation</i>
9-months turnover	20.9	23.1	27.7	25.5	-8%

During the 3rd quarter of its exercise 2022, DMS Imaging recorded a consolidated turnover of 7.3 M€, a decrease of -25% in comparison with the 3rd quarter 2021.

As announced at the end of September, to face the supply difficulties, especially for some electronic components or parts during the last few months, DMS Imaging restructured its production schedule during summer (mainly in July and August 2022), leading to delivery delays from the 3rd to the 4th quarter 2022. These delays will have almost no impact on the expected level of activity over the entire exercise thanks to a sustained order book.

DMS Imaging also reminds that the 3rd quarter 2021 was a record quarter with an exceptional level of activity for the period, resulting from an important delivery of radiology tables globally, as part of a World Bank call for tenders.

At the end of the nine first months of the exercise, the consolidated turnover is established at 25.5 M€, a limited decrease of -8% in comparison with the same period last year, and a +5% growth neutralized by the exceptional contract.

Comments by activity

- In **Radiology**, the nine-months turnover reaches 21.0 M€ (-13%).

Following the extension of the distribution agreement with Fujifilm, DMS Imaging sold its first Platinum DRF X-ray table in the area Africa - Middle East during the 3rd quarter 2022. This new geographic market addressed by Fujifilm, constitutes a new growth vector for DMS Imaging.

During the 3rd quarter 2022, DMS Imaging also won, for a period of 4 years, the UniHA (cooperative of French public hospital buyers) referencing, 1st French public purchaser in the health sector. This referencing reinforces the positioning of DMS Imaging as French leader on the market segment of remote-controlled radiology tables.

Over the nine first months of the exercise, the turnover from distribution agreements (Fujifilm, Carestream and Canon) grew by +30%, and now represent 57% of the total activity in radiology, mainly in France and in the United States.

- In **Bone densitometry**, the activity has continued its really good dynamic during the 3rd quarter 2022, growing by +18%. Over the nine first months of the exercise, this activity now reaches a turnover of 4.5 M€, a sustained growth of +30%, explained in part by export sales.

Perspectives

In **Radiology**, at the occasion of the French Days of Radiology (JFR), which took place from October 7th to 10th in Paris, DMS Imaging and its partners made several presentations of the new radiology table Platinum Néo, future key product of the company whose international launch starts during the 2nd semester 2022. The presentation of this new high-end table to radiologists will continue until the end of the year at the occasion of the professional trade shows Medica from November 14th to 17th in Düsseldorf (Germany) and Radiological Society of North America from November 27th to December 1st in Chicago (United States).

The company continues its progress in the MC2 project, aiming to develop two new high-end imaging solutions, an X-ray mobile and a C-arm for operating rooms manufactured in France, which will reinforce DMS Imaging's range of products by 2024. Consecutively to the conclusion of the strategic partnership with the company Micro-X for the supply of cold cathodes X-ray tubes, the integration tests of this technology in the X-ray mobile have been continuing in the 2nd semester 2022.

In **Bone densitometry**, the order book is good, and the group works to increase its production capacities in its new production and assembly unit in order to answer to customer request in the upcoming months.

Contribution operation of the medical imaging division to DMS Imaging

In the context of the application for listing on the Euronext market in Brussels and Paris new issued actions for the contribution operation of the imaging activities of DMS Group to DMS Imaging, the instruction of the admission prospectus, submitted to control authority of the Belgian financial sector, continues.

The quotation of DMS Imaging shares remains suspended pending the publication of the admission prospectus.

Financial calendar for 2022

Date	Event
January 20 th , 2023	Publication of the 2022 annual turnover

Publication will occur after the closure of the Euronext Paris market. This date is given as an indication, it can be changed if necessary.

About DMS Imaging

Specialized in high technology for medical diagnosis, DMS Imaging is now the French leader in development, design and manufacture of RF imaging systems dedicated to radiology, bone densitometry, 3D modeling and posturology.

DMS Imaging is quoted on the Euronext market in Brussels and Paris (ISIN: BE0974289218 - memo: DMSIM).

More information on www.dms-imaging.com.

Contacts

DMS Imaging

Samuel SANCERNI CEO 04 67 50 49 00

ACTUS FINANCE

Mathieu OMNES Investors relations 01 53 67 36 92

Nawel NAAMANE Press relations 01 53 67 36 34